ESC 365 - Insights from the vicadrostat phase 2 study and implications for further clinical development

Open Access

Insights from the vicadrostat phase 2 study and implications for further clinical development

Session: Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

Topic: Aldosterone Antagonists

Speaker: Doctor R. Mentz (Durham, US)

Sponsored by Boehringer Ingelheim

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

11 presentations

0 follower

6 more presentations in this session

Welcome and introductions

The integrated nature of cardiorenal metabolic health

Speaker: Professor L. Lund (Stockholm, SE)

The role of aldosterone and its part in cardiorenal disease

Speaker: Doctor M. Costanzo (Naperville, US)

Aldosterone synthase inhibition and the future CRM treatment landscape

Speaker: Professor J. Butler (Dallas, US)

Outlook, panel discussion and Q&A

Access the full session

Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

Speakers: Doctor R. Mentz, Professor L. Lund, Doctor M. Costanzo, Professor J. Butler

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources